Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.31 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2597140 | 0.91 | CA12 (0.34) | CA12CA9DDR1 | |
| SCHEMBL2597177 | 0.88 | LIPG (0.35) | LIPGCYP1A2METAP2CA12CA9 | |
| SCHEMBL2597069 | 0.87 | CYP1A2 (0.34) | LIPGCYP1A2METAP2CA12CA9 | |
| SCHEMBL2597377 | 0.87 | LIPG (0.35) | LIPGCYP1A2METAP2CA12CA9 | |
| SCHEMBL2597209 | 0.87 | HAVCR2 (0.32) | HAVCR2 | |
| SCHEMBL2597217 | 0.87 | HAVCR2 (0.32) | HAVCR2 | |
| SCHEMBL2597063 | 0.85 | KDM4E (0.33) | LIPGCYP1A2METAP2CA12CA9 | |
| SCHEMBL2597332 | 0.84 | KDM4E (0.34) | LIPGCYP1A2METAP2CA12CA9 | |
| SCHEMBL2597072 | 0.84 | LIPG (0.37) | LIPGCYP1A2METAP2CA12CA9 | |
| SCHEMBL2597152 | 0.83 | CA12 (0.35) | CA12CA9DDR1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571865-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | Novartis AG (CH) | 2013-03-27 | — | — | EP | claimed |
| US-20130053381-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | NOVARTIS AG | 2013-02-28 | — | — | US | claimed |
| WO-2011144666-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2011-11-24 | — | — | WO | claimed |
| EP-2571865-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | Novartis AG (CH) | 2013-03-27 | — | — | EP | disclosed |
| US-20130053381-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | NOVARTIS AG | 2013-02-28 | — | — | US | disclosed |
| US-20130053381-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | NOVARTIS AG | 2013-02-28 | — | — | US | disclosed |
| US-20130053381-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | NOVARTIS AG | 2013-02-28 | — | — | US | disclosed |
| WO-2011144666-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053381-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | GRIK2, GRIK1, GRIK4 | LIPG 4823/4885CYP1A2 259/4885METAP2 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.